Referenced as a biomedical startup developing new radiopharmaceuticals, Trevarx products indicated as being used as molecular imaging biomarkers, enabling doctors and medical professionals to diagnose and guide the treatment of cancer, brain disorders, and other human diseases. Structured around development of novel radiopharmaceutical (or theranostic) platforms that - it is suggested - turn deadly diseases into manageable conditions, the firm's first product was an alpha-emitting radiotherapeutic delivering a cytotoxic radioactive astatine particle directly to the PARP-1 tumor cell nucleus, killing the cancer cell. The firm's second product is described as an accurate and safe PET biomarker for PARPi therapy, entering Phase 2 multi-center breast cancer trials in Spring 2022, led by MD Anderson Cancer Center with participation by University of Pennsylvania and Washington University at St. Louis.
